首页> 美国卫生研究院文献>AAPS PharmSciTech >Comparative Pharmacokinetic Study of Mangiferin After Oral Administration of Pure Mangiferin and US Patented Polyherbal Formulation to Rats
【2h】

Comparative Pharmacokinetic Study of Mangiferin After Oral Administration of Pure Mangiferin and US Patented Polyherbal Formulation to Rats

机译:口服芒果苷和美国专利多草药配方对大鼠进行芒果苷的药代动力学比较研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

The US patented polyherbal formulation for the prevention and management of type II diabetes and its vascular complications was used for the present study. The xanthone glycoside mangiferin is one of the major effector constituents in the Salacia species with potential anti-diabetic activity. The pharmacokinetic differences of mangiferin following oral administration of pure mangiferin and polyherbal formulation containing Salacia species were studied with approximately the same dose 30 mg/kg mangiferin and its distribution among the major tissue in Wistar rats. Plasma samples were collected at different time points (15, 30, 60, 120, 180, 240, 360, 480, 600, 1,440, 2,160, and 2880 min) and subsequently analyzed using a validated simple and rapid LC-MS method. Plasma concentration versus time profiles were explored by non-compartmental analysis. Mangiferin plasma exposure was significantly increased when administered from formulation compared to the standard mangiferin. Mangiferin resided significantly longer in the body (last mean residence time (MRTlast)) when given in the form of the formulation (3.65 h). Cmax values of formulation (44.16 μg/mL) administration were elevated when compared to equivalent dose of the pure mangiferin (15.23 μg/mL). Tissue distribution study of mangiferin from polyherbal formulation was also studied. In conclusion, the exposure of mangiferin is enhanced after formulation and administration and could result in superior efficacy of polyherbal formulation when compared to an equivalent dose of mangiferin. The results indicate that the reason which delays the elimination of mangiferin and enhances its bioavailability might the interactions of the some other constituents present in the polyherbal formulation. Distribution study results indicate that mangiferin was extensively bound to the various tissues like the small intestine, heart, kidney, spleen, and liver except brain tissue.Electronic supplementary materialThe online version of this article (doi:10.1208/s12249-014-0206-8) contains supplementary material, which is available to authorized users.
机译:本研究使用了用于预防和治疗II型糖尿病及其血管并发症的美国专利多草药制剂。 an吨酮苷芒果苷是Salacia物种中具有潜在抗糖尿病活性的主要效应子成分之一。研究了口服剂量约30 mg / kg芒果苷的纯芒果苷和含Salacia物种的多草药制剂口服后芒果苷的药代动力学差异及其在Wistar大鼠主要组织中的分布。在不同的时间点(15、30、60、120、180、240、360、480、600、1,440、2,160和2880分钟)收集血浆样品,然后使用经过验证的简单快速的LC-MS方法进行分析。通过非房室分析探索血浆浓度与时间的关系。与标准芒果苷相比,从制剂给药时芒果苷血浆暴露显着增加。当以制剂形式(3.65小时)给药时,芒果苷在体内的生存时间明显更长(最后平均停留时间(MRTlast))。与等效剂量的纯芒果苷(15.23μg/ mL)相比,制剂(44.16μg/ mL)的Cmax值升高。还研究了多草药制剂中芒果苷的组织分布。总之,与等剂量的芒果苷相比,在配制和给药后芒果苷的暴露增加,并且可以导致多草药制剂的优异功效。结果表明,延缓芒果苷消除并提高其生物利用度的原因可能与多草药配方中存在的其他一些成分相互作用。分布研究结果表明,芒果苷与脑组织以外的小肠,心脏,肾脏,脾脏和肝脏等各种组织广泛结合。电子补充材料本文的在线版本(doi:10.1208 / s12249-014-0206-8 )包含补充材料,授权用户可以使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号